Futu News, November 4, this Thursday $CLOVER BIO-B (02197.HK)$An announcement was issued. The company will issue 150 million shares, priced at HK$13.38 per share, and 500 shares per lot. It is expected to be listed on November 5.
During the public sale phase, Clover Bio-B was subscribed about 4.4 times, and the final number of shares offered for public sale was 15 million shares, accounting for about 10% of the total number of shares offered (before any over-allotment rights were exercised). A total of 17,687 valid applications were received. The first-hand winning rate was 35%, and the first-hand subscription was stable.
Furthermore, the international offering was oversubscribed, and the final number of shares offered was approximately 135 million shares, equivalent to about 90% of the total number of shares offered (before any over-allotment rights were exercised). Futu Information collates relevant data in the following table:
In terms of financing, the company's net proceeds of approximately $1.87 billion (assuming that the over-allotment rights are not exercised) will be used for the following purposes: approximately 65% will be used for R&D, production and commercialization of core products and related products; approximately 22.5% will be used for R&D, production and commercialization of other products (such as SCB-313 and SCB-420) and other potential candidate products; and approximately 12.5% will be used for working capital and other general corporate purposes.
Established in 2007, Clover Biotech is a global biotechnology company in clinical trials dedicated to developing novel vaccines and biotherapeutic candidates for infectious diseases, cancer, and autoimmune diseases. Its main...